Also, mutations in the tumor suppressor gene PTEN, the protein that inactivates the PI3K/AKT/mTOR pathway, are frequent events in GBs and are associated with therapeutic resistance (Benitez et al., 2017). Here, PTEN is linked to Guillain-Barre syndrome.